Fig. 5: Anti-miR-873-5p decreases hepatocyte apoptosis, cholangiocyte proliferation, inflammation, and fibrogenesis in Mdr2-/- mice.
From: MiR-873-5p acts as an epigenetic regulator in early stages of liver fibrosis and cirrhosis
(a) Time scheme of the anti-miR-873-5p treatment in Mdr2-/- mice (time points indicated). MiR-873-5p (b) and GNMT expression (c) in the liver of Mdr2-/- and anti-miR-873-Mdr2-/- mice. (d) Serum transaminases levels expressed as fold change from the initial values and (e) bile acid content in Mdr2-/- mice. (f) CK19, Cleaved Caspase 3, ammonia, F4/80, and Sirius red staining in liver sections from miR-Ctrl and miR-873-5p-inhibited Mdr2 -/- mice. Densitometry analyses of WB are shown in Supp. Fig. 6C. Data normalized as fold change vs. control. Error bars represent the means ± SEM (N = 5). Statistical significance was determined by the Student’s t-test or ANOVA when more than two groups were compared p < 0.05*; p < 0.01**; p < 0.001 ***. ----- line in d indicates initial levels of the measurements
